Open AccessTreatment of Stage I hard palate cancer with high-dose-rate brachytherapy using molds: Cost-based perspective
Author(s) -
Kranti Kiran Reddy Ealla,
Sri Krishna C Prakash,
Prasanna Manidanappanavar,
Sowmya Katthuri,
Keerthika Gurram,
Thakur Kshatri Shyamilee
Publication year - 2019
Publication title -
journal of pharmacy and bioallied sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.268
H-Index - 36
eISSN - 0976-4879
pISSN - 0975-7406
DOI - 10.4103/jpbs.jpbs_193_18
Subject(s) - brachytherapy , stage (stratigraphy) , perspective (graphical) , medicine , hard palate , medical physics , dose rate , oncology , dentistry , radiology , computer science , radiation therapy , artificial intelligence , biology , paleontology
Treatment of T1N0M0 (T1 = greatest tumor size < 2 cm, N0 = regional lymph nodes not palpable by clinical examination, M0 = No evidence of distant metastasis) (Green FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M. AJCC Cancer Staging Manual. New York: Springer; 2002) lesions of hard palate carcinoma by radiotherapy carries equal results with the advantage of cosmesis and can avoid surgical complications. External beam radiotherapy (EBRT) will last for 6-8 weeks. Feasibility of high-dose-rate (HDR) intraoral mold brachytherapy is an alternative to EBRT, which is highly effective and reduces treatment time and is also cost-effective one, which can be practiced in a center without Linac facilities.